Innovative Solutions for Life Science Challenges

PROFESSIONAL SUMMARY

Accomplished molecular and cellular biologist with expertise in virology, immunology, antibody engineering, biomaterials, and translational neuroscience. Proven leader in biotechnology innovation with a track record of translating fundamental biological research into applied therapeutics, including vaccine development, antibody technologies, and biomaterials. Currently engaged in AI-driven immunology research exploring the theoretical limits of immune recognition. Experienced educator and mentor with adjunct faculty appointments and a commitment to student-centered teaching and applied scientific learning.

CORE COMPETENCIES

• Molecular and Cellular Biology 
• Immunology and Virology 
• Vaccine Development and Antibody Engineering 
• AI-Driven Immunology and Computational Modeling 
• Translational Research and Therapeutic Development 
• Host–Pathogen Interactions 
• Protein Engineering and Recombinant Systems 
• Biomaterials and Tissue Engineering 
• Scientific Communication and Technical Writing 
• Interdisciplinary Research and Collaboration 
• Experimental Design and Data Interpretation 
• Grant Development and Scientific Strategy 
• Biotechnology Leadership and R&D Management 
• Teaching, Mentorship, and Curriculum Development

RESEARCH INTERESTS

• Molecular mechanisms of viral pathogenesis 
• Vaccine development and adjuvant systems 
• Antibody engineering and protein production 
• AI-driven immunology and computational modeling 
• Host–pathogen interactions 
• Cellular therapies and regenerative medicine 
• Tissue engineering and biomaterials 

PROFESSIONAL EXPERIENCE

Founder & Principal Scientist, AI-Driven Immunology Research

Stephen Hall, PhD (2023–Present)

• Developing AI-driven models to investigate the theoretical limits of immune system recognition in multivalent virus-like particle (VLP) systems 
• Analyzing the relationship between epitope diversity and immune response capacity 
• Exploring upper bounds of antigenic complexity in adaptive immune recognition 
• Applying computational and immunological approaches to inform next-generation vaccine design strategies 
• Integrating molecular immunology with computational modeling to evaluate antigen presentation and immune prioritization 

Founder, CEO & CSO

Stephen Hall, PhD, Ltd (1998–2023)

• Directed research in antibody engineering and biomaterial development 
• Led translational research programs bridging basic science and applied therapeutics 
• Oversaw scientific strategy, R&D operations, and interdisciplinary teams 
• Company acquired (2023) 

Founder, CEO & CSO

Pentamer Pharmaceuticals, Inc (1997–2002)

• Founded and led a biotechnology company focused on vaccine development and immunological technologies 
• Secured venture funding from Johnson & Johnson Development Corporation and GeneChem Technologies Venture Fund 
• Directed development of recombinant platforms and adjuvant systems 
• Company acquired by Johnson & Johnson (2002) 

POSTDOCTORAL RESEARCH EXPERIENCE

Research Fellow

Medical Biology Institute (now Avanir Pharmaceuticals) (1996–1997)

• Conducted research in cancer immunology and immune system interactions 

Postdoctoral Research Associate

The Scripps Research Institute (1995–1997)

• Conducted molecular and structural virology research 
• Investigated viral mechanisms and host-pathogen interactions 
• Sole inventor of viral-like particle technology that led to formation of Pentamer Pharmaceuticals, Inc.

EARLY RESEARCH EXPERIENCE

Research Assistant, Department of Neurosurgery

Barrow Neurological Institute (1987–1990)

• Supported laboratory and translational research focused on the chemistry of NMDA receptors in a baboon model of ischemic stroke
• Contributed to experimental studies involving neural systems in a clinical research environment 

ACADEMIC APPOINTMENTS

Adjunct Professor, EPICS (Engineering Projects in Community Service)

Purdue University (2011–2012)

• Led interdisciplinary student teams in biomedical engineering design projects addressing real-world challenges 

Adjunct Professor, Biomedical Engineering

University of South Dakota (2008–2010)

Adjunct Professor, Molecular and Cellular Biology

San Diego State University (1998–2000)

EARLY TEACHING & ACADEMIC EXPERIENCE

• Instructor, Molecular Neurobiology (Summer Programs), Cold Spring Harbor Laboratory (1991–1993) 
• Student Representative, Executive Committee, Purdue University Neuroscience Program (1990–1995) 

SELECTED PUBLICATIONS & PATENTS

Harting, M. T., Cox, C. S., & Hall, S. G. (2009).
Preclinical Evidence for Cellular Therapy as a Treatment for Neurological Disease.
In Rajasekhar, V. K., & Vemuri, M. C. (Eds.), Regulatory Networks in Stem Cells: Stem Cell Biology and Regenerative Medicine. Humana Press.

Zeigler, F., & Hall, S. G. (2007).
Isolation of oligodendroglial cells from cultured neural stem/progenitors.
Methods in Molecular Biology, 407, 323–331.

Recombinant Nodavirus Compositions and Methods

· U.S. Patent: US6171591B1 

· International (PCT): WO1999029723A1

GRANTS & FUNDING

• NIH SBIR Grant (1998), Development of Highly Diverse Antibody Display Libraries 
• Venture Funding (1998), Secured venture funding from Johnson & Johnson Development Corporation and GeneChem Technologies Venture Fund 

EDUCATION

Ph.D., Molecular & Cellular Biology
Purdue University (1995)
American Cancer Society Fellow (1993–1995)

B.S., Chemistry
Grand Canyon University (1990)

HONORS & AWARDS

• Grand Canyon University, College of Science, Engineering and Technology, Alumni Hall of Fame (2015) 
• American Cancer Society Fellow, Purdue University (1993–1995) 

MILITARY SERVICE

United States Army / Army National Guard (1973–1980)
Sergeant (E-5), Field Artillery

• Served as Section Chief in an M109 self-propelled 155mm battery 
• Initially trained in Air Defense Artillery before transitioning to Field Artillery 
• Honorably discharged; Protected veteran with service-connected disabilities.